A

Agios Pharmaceuticals
D

AGIO

30.060
USD
-0.85
(-2.75%)
مغلق
حجم التداول
22,708
الربح لكل سهم
-7
العائد الربحي
-
P/E
3
حجم السوق
1,740,930,882
أصول ذات صلة
B
BLUE
-0.15000
(-3.69%)
3.91000 USD
BMRN
BMRN
-0.700
(-1.12%)
61.980 USD
C
CRSP
0.520
(1.38%)
38.220 USD
E
EDIT
0.01500
(0.93%)
1.63000 USD
E
EXEL
0.700
(1.80%)
39.600 USD
GILD
GILD
0.420
(0.41%)
103.660 USD
N
NKTR
-0.02630
(-3.38%)
0.75210 USD
S
SRPT
0.740
(1.18%)
63.550 USD
المزيد
الأخبار المقالات

العنوان: Agios Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.